Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)

Robyn H Guymer1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia;3 Royal Victorian Eye and EAR Hospital, Melbourne, Australia

Peter N Dimitrov1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia

Mary Varsamidis1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia

Lyndell L Lim1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia;3 Royal Victorian Eye and EAR Hospital, Melbourne, Australia

Paul N Baird1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia

Algis J Vingrys2 Department of Optometry and Visual Sciences, University of Melbourne, Melbourne, Victoria, Australia

Luba Robman1 Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia;3 Royal Victorian Eye and EAR Hospital, Melbourne, AustraliaCorrespondence[email protected]

show all

Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date